Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 23,378 shares at $150.60 ($3.7M) on 2024-05-22, disclosed to the SEC on 2024-05-24.
Scheduled sale ($3.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $142.95 | 100 | $14K | 0.4% |
| 2 | $144.40 | 200 | $29K | 0.8% |
| 3 | $145.03 | 100 | $15K | 0.4% |
| 4 | $147.06 | 300 | $44K | 1.2% |
| 5 | $148.21 | 600 | $89K | 2.4% |
| 6 | $149.45 | 300 |
| $45K |
| 1.2% |
| 7 | $150.60 | 400 | $60K | 1.6% |
| 8 | $151.73 | 700 | $106K | 2.9% |
| 9 | $152.92 | 800 | $122K | 3.3% |
| 10 | $152.92 | 800 | $122K | 3.3% |
| 11 | $153.84 | 200 | $31K | 0.8% |
| 12 | $155.66 | 600 | $93K | 2.5% |
| 13 | $157.41 | 1,802 | $284K | 7.7% |
| 14 | $157.41 | 1,802 | $284K | 7.7% |
| 15 | $158.25 | 1,923 | $304K | 8.2% |
| 16 | $158.25 | 1,923 | $304K | 8.2% |
| 17 | $159.57 | 2,200 | $351K | 9.5% |
| 18 | $160.24 | 825 | $132K | 3.6% |
| 19 | $162.19 | 1,005 | $163K | 4.4% |
| 20 | $162.19 | 1,005 | $163K | 4.4% |
| 21 | $163.02 | 2,223 | $362K | 9.8% |
| 22 | $163.02 | 2,223 | $362K | 9.8% |
| 23 | $163.92 | 625 | $102K | 2.8% |
| 24 | $163.92 | 625 | $102K | 2.8% |
| 25 | $164.67 | 97 | $16K | 0.4% |
| Total | $158.34 avg | 23,378 | $3.7M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |